ATE443526T1 - Zusammensetzung für perkutane absorption mit einem melantoninrezeptor-agonistisch wirkendem wirkstoff - Google Patents

Zusammensetzung für perkutane absorption mit einem melantoninrezeptor-agonistisch wirkendem wirkstoff

Info

Publication number
ATE443526T1
ATE443526T1 AT00953481T AT00953481T ATE443526T1 AT E443526 T1 ATE443526 T1 AT E443526T1 AT 00953481 T AT00953481 T AT 00953481T AT 00953481 T AT00953481 T AT 00953481T AT E443526 T1 ATE443526 T1 AT E443526T1
Authority
AT
Austria
Prior art keywords
melantonin
percutane
composition
active ingredient
receptor agonistic
Prior art date
Application number
AT00953481T
Other languages
English (en)
Inventor
Yasuyuki Suzuki
Katsumi Iga
Masaomi Miyamoto
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Application granted granted Critical
Publication of ATE443526T1 publication Critical patent/ATE443526T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00953481T 1999-08-20 2000-08-18 Zusammensetzung für perkutane absorption mit einem melantoninrezeptor-agonistisch wirkendem wirkstoff ATE443526T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP23410699 1999-08-20
PCT/JP2000/005525 WO2001013950A1 (fr) 1999-08-20 2000-08-18 Agents d'absorption percutanee

Publications (1)

Publication Number Publication Date
ATE443526T1 true ATE443526T1 (de) 2009-10-15

Family

ID=16965732

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00953481T ATE443526T1 (de) 1999-08-20 2000-08-18 Zusammensetzung für perkutane absorption mit einem melantoninrezeptor-agonistisch wirkendem wirkstoff

Country Status (7)

Country Link
US (2) US20090264521A1 (de)
EP (1) EP1214944B1 (de)
AT (1) ATE443526T1 (de)
AU (1) AU6595100A (de)
CA (1) CA2381468C (de)
DE (1) DE60043017D1 (de)
WO (1) WO2001013950A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2001278754A1 (en) * 2000-08-18 2002-03-04 Takeda Chemical Industries Ltd. Tricyclic compounds and pharmaceutical compositions containing the same
DE10154324A1 (de) * 2001-11-06 2003-08-07 Merz Pharma Gmbh & Co Kgaa Topisch applizierbare Zusammensetzungen mit externer Wirkstoffdepotbildung, deren Herstellung sowie deren Verwendung
EP1696959A2 (de) * 2003-12-24 2006-09-06 Sepracor, Inc. Melatonin-kombinationstherapie zur verbesserung der schlafqualität
US20060223877A1 (en) * 2005-03-31 2006-10-05 Zemlan Frank P Methods of treatment utilizing certain melatonin derivatives
EP2275096A3 (de) * 2005-08-26 2011-07-13 Braincells, Inc. Neurogenese durch modulation des Muscarinrezeptors
AR061478A1 (es) 2006-06-19 2008-08-27 Takeda Pharmaceutical Compuesto triciclico y composicion farmaceutica
KR20110041495A (ko) * 2008-07-30 2011-04-21 페레르 인터내쇼날 에스.에이. 1,6-디하이드로-2ｈ-3-옥사-6-아자-ａｓ-인다세네 화합물
JP5636715B2 (ja) * 2009-03-27 2014-12-10 トーアエイヨー株式会社 経皮吸収製剤
WO2010109913A1 (ja) * 2009-03-27 2010-09-30 トーアエイヨー株式会社 経皮吸収製剤
JP5664991B2 (ja) * 2009-03-27 2015-02-04 トーアエイヨー株式会社 経皮吸収製剤
WO2016104227A1 (ja) * 2014-12-22 2016-06-30 久光製薬株式会社 パップ剤
ES2738633T3 (es) * 2015-02-04 2020-01-24 Soeur Josefa Menendez Sistema terapéutico transdérmico que contiene valentonina y su uso como medicamento

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5750134A (en) * 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
IT1254995B (it) 1992-06-24 1995-10-11 Farmaco contenente melatonina e/o agonisti, con somministrazione particolarmente efficace nelle patologie che interferiscono con i ritmi circandiani
US6271015B1 (en) * 1995-06-12 2001-08-07 The Scripps Research Institute Fatty-acid amide hydrolase
JPH09160821A (ja) * 1995-12-01 1997-06-20 Matsushita Electric Ind Co Ltd ハイパーテキスト文書作成装置
US6054484A (en) * 1996-02-07 2000-04-25 Tsumura & Co. Transparent aqueous solution of diclofenac sodium and medicinal compositions with the use of the same
SK283970B6 (sk) * 1996-03-08 2004-06-08 Takeda Chemical Industries, Ltd. Tricyklické zlúčeniny, spôsob výroby a farmaceutický prípravok ich obsahujúci
US6034239A (en) * 1996-03-08 2000-03-07 Takeda Chemical Industries, Ltd. Tricyclic compounds, their production and use
JP2884153B2 (ja) 1996-03-08 1999-04-19 武田薬品工業株式会社 三環性化合物、その製造法および剤
US5736154A (en) * 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
JPH1029933A (ja) 1996-07-17 1998-02-03 Teisan Seiyaku Kk メラトニン含有貼付剤
JPH1029934A (ja) 1996-07-17 1998-02-03 Teisan Seiyaku Kk メラトニンを含有する貼付剤
JP2001502693A (ja) * 1996-10-24 2001-02-27 アルザ コーポレイション 経皮薬物投与組成物、装置、および方法に適した透過促進剤
JPH10182455A (ja) 1996-12-24 1998-07-07 Teisan Seiyaku Kk メラトニン含有貼付剤
JP4275751B2 (ja) * 1996-12-27 2009-06-10 久光製薬株式会社 外用組成物

Also Published As

Publication number Publication date
US20090264521A1 (en) 2009-10-22
DE60043017D1 (de) 2009-11-05
EP1214944A4 (de) 2005-03-16
US20120309823A1 (en) 2012-12-06
CA2381468C (en) 2013-05-28
AU6595100A (en) 2001-03-19
EP1214944A1 (de) 2002-06-19
CA2381468A1 (en) 2001-03-01
WO2001013950A1 (fr) 2001-03-01
EP1214944B1 (de) 2009-09-23

Similar Documents

Publication Publication Date Title
ATE443526T1 (de) Zusammensetzung für perkutane absorption mit einem melantoninrezeptor-agonistisch wirkendem wirkstoff
ES2096312T3 (es) Derivado de quinuclidina como antagonista de la sustancia p.
MX9204881A (es) Composicion farmaceutica que comprende moleculas activas, receptoras de calcio.
BRPI0108977B8 (pt) compostos azacíclicos, composição farmacêutica e uso de um composto ou sal farmaceuticamente aceitável do mesmo
EA200000468A1 (ru) Терапевтическая композиция для введения толтеродина с контролируемым высвобождением
NL300232I1 (nl) Gebruik van daptomycine.
IL147852A0 (en) Chemokine receptor antagonists and pharmaceutical compositions containing the same
EA200501332A1 (ru) Производные пиримидин-4-она и их применение в качестве модуляторов киназы p38
NO20022442D0 (no) Legemidler for sykdommer i forbindelse med reduksjon i benmasse
BR0112661A (pt) Nova combinação de agonista (5ht2) e antagonista (5ht6) da serotonina como formulação farmacêutica
DE69322251T2 (de) Medizinische zusammensetzung
RU2008127260A (ru) Производные хиназолинона в качестве антагонистов ваниллоидов
ATE337333T1 (de) Ophthalmische arzneimittelzusammenstellung
ATE487491T1 (de) Präparationen zur perkutanen aufnahme von zusammnesetzungen die einen angiotensin-ii- rezeptorantagonismus aufweisen
RU2007143337A (ru) Фармацевтическая композиция на основе пептида, регулирующего нарушения ангиогенеза, и способ ее применения
CY1112190T1 (el) Θεραπεια της εξαρτωμενης απο το μηκος νευροπαθειας
EP0097953A3 (de) Synergistische Zusammensetzungen von Nalbuphin und nicht narkotischen analgetischen Verbindungen
TW360629B (en) Calcium receptor active molecules
EP0979818A4 (de) Benzoesäurederivate und deren medizinische verwendung
FR2691630B1 (fr) Composition pharmaceutique, en particulier pour l'administration orale, contenant, comme ingrédient actif, un agoniste sélectif des récepteurs de type 5HT1.
GB9211277D0 (en) Pharmaceutical compositions

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties